Literature DB >> 22727807

A novel ultrasensitive LC-MS/MS assay for quantification of intracellular raltegravir in human cell extracts.

Brian L Robbins1, Sarah R Nelson, Courtney V Fletcher.   

Abstract

An assay using ultrahigh pressure liquid chromatography and mass spectrometry detection was developed and validated for measurement of the HIV integrase inhibitor raltegravir (MK-0518) in human cell extracts. The assay is designed to utilize 200 μl of 70% MeOH cell extract derived from human peripheral blood mononuclear cells or human tissue samples. The assay is linear over a range from 0.0023 to 9.2 ng ml(-1). The average %CV (SD/Mean)*100 and %deviation ((observed-target)/target)*100 were less than 20% at the lower limit of quantification and less than 15% over the range of the curve. This assay is an accurate and highly sensitive method for determining raltegravir concentrations in cellular extracts with a lower limit 40 to over 100-fold lower than other methods in the literature. We also present a new processing method where a rapid spin through oil produced a significant increase in apparent intracellular raltegravir concentration compared with conventional processing.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22727807      PMCID: PMC3443311          DOI: 10.1016/j.jpba.2012.05.035

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  16 in total

1.  Quantitation of zidovudine triphosphate concentrations from human peripheral blood mononuclear cells by anion exchange solid phase extraction and liquid chromatography-tandem mass spectroscopy; an indirect quantitation methodology.

Authors:  Tracy King; Lane Bushman; Peter L Anderson; Thomas Delahunty; Michelle Ray; Courtney V Fletcher
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2006-01-10       Impact factor: 3.205

2.  Simultaneous measurement of intracellular triphosphate metabolites of zidovudine, lamivudine and abacavir (carbovir) in human peripheral blood mononuclear cells by combined anion exchange solid phase extraction and LC-MS/MS.

Authors:  Brian L Robbins; Philip A Poston; Erin F Neal; Clive Slaughter; John H Rodman
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2006-12-17       Impact factor: 3.205

3.  Liquid chromatography-tandem mass spectrometric determination of tenofovir-diphosphate in human peripheral blood mononuclear cells.

Authors:  Tracy King; Lane Bushman; Jennifer Kiser; Peter L Anderson; Michelle Ray; Thomas Delahunty; Courtney V Fletcher
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2006-07-07       Impact factor: 3.205

4.  A rapid technique for separation of thymocytes from suspensions by centrifugation through silicone oil.

Authors:  P A Andreasen; B P Schaumburg; K Osterline; J Vinten; S Gammeltoft; J Gliemann
Journal:  Anal Biochem       Date:  1974-06       Impact factor: 3.365

5.  Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals.

Authors:  Martin Markowitz; Javier O Morales-Ramirez; Bach-Yen Nguyen; Colin M Kovacs; Roy T Steigbigel; David A Cooper; Ralph Liporace; Robert Schwartz; Robin Isaacs; Lucinda R Gilde; Larissa Wenning; Jing Zhao; Hedy Teppler
Journal:  J Acquir Immune Defic Syndr       Date:  2006-12-15       Impact factor: 3.731

6.  Nucleoside uptake and membrane fluidity studies on N-trifluoroacetyladriamycin-14-O-hemiadipate-treated human leukemia and lymphoma cells.

Authors:  J Lameh; R Y Chuang; M Israel; L F Chuang
Journal:  Cancer Res       Date:  1989-06-01       Impact factor: 12.701

7.  A human T lymphoid cell variant resistant to the acyclic nucleoside phosphonate 9-(2-phosphonylmethoxyethyl)adenine shows a unique combination of a phosphorylation defect and increased efflux of the agent.

Authors:  B L Robbins; M C Connelly; D R Marshall; R V Srinivas; A Fridland
Journal:  Mol Pharmacol       Date:  1995-02       Impact factor: 4.436

8.  Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial.

Authors:  Jeffrey L Lennox; Edwin DeJesus; Adriano Lazzarin; Richard B Pollard; Jose Valdez Ramalho Madruga; Daniel S Berger; Jing Zhao; Xia Xu; Angela Williams-Diaz; Anthony J Rodgers; Richard J O Barnard; Michael D Miller; Mark J DiNubile; Bach-Yen Nguyen; Randi Leavitt; Peter Sklar
Journal:  Lancet       Date:  2009-08-03       Impact factor: 79.321

9.  Raltegravir.

Authors:  Jamie D Croxtall; Katherine A Lyseng-Williamson; Caroline M Perry
Journal:  Drugs       Date:  2008       Impact factor: 9.546

10.  Plasma and intracellular pharmacokinetics of darunavir/ritonavir once daily and raltegravir once and twice daily in HIV-infected individuals.

Authors:  Akil Jackson; Victoria Watson; David Back; Saye Khoo; Neill Liptrott; Deidre Egan; Keerti Gedela; Chris Higgs; Riaz Abbas; Brian Gazzard; Marta Boffito
Journal:  J Acquir Immune Defic Syndr       Date:  2011-12-15       Impact factor: 3.731

View more
  9 in total

1.  Correlation between plasma, intracellular, and cervical tissue levels of raltegravir at steady-state dosing in healthy women.

Authors:  Caroline Mitchell; Emily Roemer; Evangelyn Nkwopara; Brian Robbins; Theodore Cory; Tessa Rue; Courtney V Fletcher; Lisa Frenkel
Journal:  Antimicrob Agents Chemother       Date:  2014-03-31       Impact factor: 5.191

2.  Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues.

Authors:  Courtney V Fletcher; Kathryn Staskus; Stephen W Wietgrefe; Meghan Rothenberger; Cavan Reilly; Jeffrey G Chipman; Greg J Beilman; Alexander Khoruts; Ann Thorkelson; Thomas E Schmidt; Jodi Anderson; Katherine Perkey; Mario Stevenson; Alan S Perelson; Daniel C Douek; Ashley T Haase; Timothy W Schacker
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-27       Impact factor: 11.205

Review 3.  Eradicating HIV-1 infection: seeking to clear a persistent pathogen.

Authors:  Nancie M Archin; Julia Marsh Sung; Carolina Garrido; Natalia Soriano-Sarabia; David M Margolis
Journal:  Nat Rev Microbiol       Date:  2014-11       Impact factor: 60.633

4.  A rapid spin through oil results in higher cell-associated concentrations of antiretrovirals compared with conventional cell washing.

Authors:  Theodore J Cory; Lee C Winchester; Brian L Robbins; Courtney V Fletcher
Journal:  Bioanalysis       Date:  2015       Impact factor: 2.681

5.  Cervicovaginal and Rectal Fluid as a Surrogate Marker of Antiretroviral Tissue Concentration: Implications for Clinical Trial Design.

Authors:  Mackenzie L Cottrell; Heather M A Prince; Andrew Allmon; Katie R Mollan; Michael G Hudgens; Craig Sykes; Nicole White; Stephanie Malone; Evan S Dellon; Ryan D Madanick; Nicholas J Shaheen; Kristine B Patterson; Angela D M Kashuba
Journal:  J Acquir Immune Defic Syndr       Date:  2016-08-15       Impact factor: 3.731

Review 6.  Antiretroviral bioanalysis methods of tissues and body biofluids.

Authors:  Robin DiFrancesco; Getrude Maduke; Rutva Patel; Charlene R Taylor; Gene D Morse
Journal:  Bioanalysis       Date:  2013-02       Impact factor: 2.681

7.  Differential penetration of raltegravir throughout gastrointestinal tissue: implications for eradication and cure.

Authors:  Kristine B Patterson; Heather A Prince; Trenton Stevens; Nicholas J Shaheen; Evan S Dellon; Ryan D Madanick; Steven Jennings; Myron S Cohen; Angela D M Kashuba
Journal:  AIDS       Date:  2013-06-01       Impact factor: 4.177

8.  Antiretroviral Therapy Concentrations Differ in Gut vs. Lymph Node Tissues and Are Associated With HIV Viral Transcription by a Novel RT-ddPCR Assay.

Authors:  Sulggi A Lee; Sushama Telwatte; Hiroyu Hatano; Angela D M Kashuba; Mackenzie L Cottrell; Rebecca Hoh; Teri J Liegler; Sophie Stephenson; Ma Somsouk; Peter W Hunt; Steven G Deeks; Steven Yukl; Radojka M Savic
Journal:  J Acquir Immune Defic Syndr       Date:  2020-04-15       Impact factor: 3.771

9.  Selective and rapid determination of raltegravir in human plasma by liquid chromatography-tandem mass spectrometry in the negative ionization mode.

Authors:  Ajay Gupta; Swati Guttikar; Priyanka A Shah; Gajendra Solanki; Pranav S Shrivastav; Mallika Sanyal
Journal:  J Pharm Anal       Date:  2014-10-23
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.